FDA Tightens Scrutiny of OTC Eye Drop Manufacturers Following Contamination-Linked Recalls

A sustained wave of contamination-related recalls has placed ophthalmic drug manufacturers under intensified FDA regulatory scrutiny, with sterility assurance and facility registration compliance now functioning as primary inspection triggers for the sector. The agency's published guidance makes clear that risk-based inspection targeting is active, not passive, and that manufacturers of both prescription and OTC ophthalmic products should treat current enforcement signals as a readiness benchmark.

The operational basis for concern is concrete. Recalls spanning 2023 through 2024 implicated products from multiple manufacturers, including a fungal contamination event at Alcon Laboratories affecting Systane Lubricant Eye Drops Ultra PF (Lot 10101) in December 2024, and a potential lack-of-sterility recall involving Brassica Pharma Pvt. Ltd. covering several private-label lubricant eye ointments. Earlier actions targeted EzriCare Artificial Tears and MSM-containing products, with documented patient outcomes including infection, partial vision loss, and blindness.

FDA's stated framework positions surveillance sampling, adverse event monitoring, and risk-based facility selection as the three levers driving inspection scheduling. For QA directors, this means contamination signals in post-market surveillance data, unresolved CAPA documentation, or gaps in 21 CFR Part 211 compliance are the variables most likely to elevate a facility's inspection priority. The agency has also reaffirmed that all facilities manufacturing eye drops marketed in the U.S. must maintain current FDA registration, a baseline requirement that enforcement history suggests is not universally met.

The sterility dimension is non-negotiable for ophthalmic products: the eye's direct exposure pathway bypasses mucosal and systemic defenses, making any contamination event a patient safety incident rather than a quality deviation. Preservative systems in multi-dose containers carry particular scrutiny, as their failure mode directly enables microbial proliferation between uses. Manufacturers operating multi-dose fill lines should review preservative efficacy data against current compendial standards as a proactive inspection-readiness measure.

The agency has also flagged a parallel enforcement concern around unapproved and homeopathic ophthalmic products containing ingredients including silver sulfate, MSM, honey, and CBD, none of which have a legally marketed ophthalmic drug pathway in the U.S. Facilities or distributors with any supply-chain adjacency to these product categories face warning letter exposure independent of GMP standing.

With FDA's risk-based inspection cadence now explicitly tied to post-market contamination signals, the next inspection cycle for ophthalmic manufacturers will likely reflect the cumulative recall record of the past 24 months as a selection criterion.

Source: U.S. Food and Drug Administration via FDA.gov, June 15, 2026.